March 18, 2019
FDA: Hospira recalls 8.4% Sodium Bicarbonate Injection
Editor's Note
The Food and Drug Administration (FDA) on March 15 announced the recall by Hospira, Inc (a Pfizer company) of three lots of its 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL).
The recall was initiated because of the presence of particulate matter, confirmed as glass.
The lots and expiration dates are:
- 79-238-EV (Exp July 1, 2019)
- 79-240-EV (Exp July 1, 2019)
- 80-088-EV (Exp August 1, 2019).
The affected lots were distributed from August 2017 to September 2017.
Free Daily News
- Routine preop tests catch hidden risks in outpatient cosmetic surgery, Canadian study finds
- Study: Hospital same‑day knee replacements match ASC outcomes, even in higher‑risk patients
- FDA clears AI platform for real-time surgical measurements
- Study: MRI contrast agent causes harmful metal buildup in some patients
- Dissolvable pacemaker delivers temporary cardiac support without wires, surgery
- CSA taps Milagro’s AI coding to accelerate revenue cycle across ASC network
- Study: Cannabis use complicates sedation, cancer care
- Medication vial coring incidents prompt patient safety concerns
- First single-port robotic renal vein transposition surgery treats nutcracker syndrome
- Study: Mortality prediction models fail to recognize severe patient injuries
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement